Biomed’s team has discovered a new family of drugs for the treatment and prevention of Alzheimer’s disease.
The drug NA-831™is a small molecule drug that can be administered orally. The drug NA-831 can easily crosses the blood brain barrier. NA-831™ exhibits neuroprotection to protect the brain from further damages. The drug exhibits strong neurogenesis, i.e. ability to generate new neurons.
How does NA-831™work?It has been discovered that in Alzheimer’s patients, the ability to regenerate new neurons in the hippocampus is impaired, causing memory loss and cognitive impairment. Our drug, NA-831 facilitates neurogenesis restoring memory loss and improve cognitive functions.
NA-831 which is based on mechanism of action of neurogenesis, directly related to restoring memory loss and improvement of cogntive improvement.
The drug NA-831 can easily crosses the blood brain barrier, so only a small dose of the drug is required to be effective. The drug shows the following properties:
NeuroActiva has conducted a Randomized Double-Blind Placebo-Controlled Phase 2A Clinical Trial of NA-831 in Patients with MCI and Mild and Moderate Alzheimer’s Disease on 32 patients with mild cognitive impairment and 24 patients with mild and moderate Alzheimer’s disease.
Based on the Brief Cognitive Rating Scale (BCRS,) the effects of NA-831 were apparent after 14 weeks of treatment (p=0.01), with the significant improvement after 24 weeks in the following areas:
In addition, patients had significant quality of life improvements, with less fatigue, anxiety, irritability, affective lability, disturbance to waking, daytime drowsiness, headache, and nocturnal sleep.
NA-831 was well-tolerated with no adverse events or concerning safety signals. In addition, there was a significant improvement in the memory test performance for the Alzheimer’s patients in the study who were administered NA-831 compared to placebo.
NA-831 showed a significant improvement for patients with mild and moderate AD with the ADAS-Cog score changed of an average of 4.1 as compared to the placebo after 24 weeks of treatment . The Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) showed 82.1% patients improved.
The topline results of the Phase 2A of NA-831 was presented at the Alzheimer Association International Conference (AAIC) - July 25, 2018 in Chicago and the follow-up results were given at the AAIC, July 17, 2019 in Los Angeles.
Neuroactiva plans to conduct two Phase 3 programs for NA-831:
(1) The COGNITION Program for the treatment of 375 patients with mild and moderate Alzheimer’s disease over 12 months. Age group: 65- 80 years of age.
(2) The PREVENTION Program for the prevention of 550 subjects, asymptomatic from a high risk population over 24 months. Age group: 45-70 years of age.
These trials follow strict scientific standards and regulatory requirements to protect patients and help produce reliable results.
Study physicians will review risks and potential benefits with patients and their caregivers before patients are enrolled in the clinical trials.
The Phase 3 clinical trials of NA-831 have been designed to evaluate its safety and efficacy as required by the US Food and Drug Administration (FDA) and other regulators overseas before being approved for usage and marketing worldwide.
Vineurocin (NA704) can be shown to modulate the aging process in humans. NA-704 can also regulate cell growth and development, especially in nerve cells, as well as cellular DNA synthesis.
In preclinical studies, NA-704 is able to stimulate regeneration of neurons, outgrowth of electrically active fibers, restoration of neuronal function, and reduction of muscular spasticity.
NA-704™ is associated with potential reversal of degeneration of neuron axons in certain peripheral neuropathies.
NA-704™ exhibits neuroprotection and neurogenesis, which has been demonstrated as a strong candidate for treatment of Alzheimer’s disease and other neurological disorders. NA-704 is to be administered intravenously once a week, per prescription of a qualified physician. br>
NA-704 has excellent proof of safety in Phase 1 clinical trial. Phase 2 of NA-704 will start in 2022.
For further information about our products, please contact us. Contact us
The hippocampus is essential for learning and memory formation and one of the first brain regions affected in the development of Alzheimer’s disease (AD). In the hippocampus, new neurons are generated throughout life via a process called adult hippocampal neurogenesis (AHN).
In mild cognitive impairment (MCI) and mild to moderate AD (early AD), AHN is reduced suggesting that AHN impairment compromises hippocampal function. Accordingly, augmenting AHN could help prevent or slow cognitive decline in MCI and early AD.
NA-831 restores neurogenesis by activating synaptic AMPA receptors, and increases the expression of BDNF (brain derived neurotrophic factor). BDNF is crucial in synaptic plasticity, learning and memory formation in the hippocampus.
Traneuroci™ or NA-831 provides neuroprotection and catalyzing the regeneration of new neurons. Oral 30 mg per day for patients with early onset of Alzheimer’s Disease. NA-831 is manufactured by NeuroActiva, a subsidiary of Biomed.
Learn more
In Alzheimer’s patients, the ability to regenerate new neurons in the hippocampus is impaired, causing memory loss and cognitive disorders. NA-831 facilitates neurogenesis restoring memory loss and improve cognitive functions.
Learn more
Biomed is conducting Phase 3 clinical trials of NA-831 for the treatment and prevention of Alzheimer’s disease. We also conduct Phase 2/3 trials of NA-831 in combination with Atazanavir, Remdesivir, and Dexaneurosone and Ivermectin for treating Covid-19
Learn more
Vineurocin (NA-704) is an injectable drug, to regenerate new neurons, and reducting of muscular spasticity, a strong candidate for treatment of Alzheimer’s disease and Parkinson’s disease. NA-704 can be administered with the MICROS. NA-704 is in the Phase 1 safety studies.
Learn more
Combination therapy of NA-831 and an antiviral drugs such as Atazanavir, Remdesivir (Gilead Sciences) and anti-inflammatory such as Dexaneurosone and Ivermectin can enhance the effectiveness of the treatment of Covid-19.
Learn more
